These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 32473188)
21. Nanocarriers as Administration Systems of Natural Products. Solís-Cruz GY; Pérez-López LA; Alvarez-Roman R; Rivas-Galindo VM; Silva-Mares DA; Ibarra-Rivera TR Curr Top Med Chem; 2021; 21(26):2365-2373. PubMed ID: 34525921 [TBL] [Abstract][Full Text] [Related]
22. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889 [TBL] [Abstract][Full Text] [Related]
23. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. Narasimhan C; Mach H; Shameem M Ther Deliv; 2012 Jul; 3(7):889-900. PubMed ID: 22900469 [TBL] [Abstract][Full Text] [Related]
24. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
25. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. Zhao L; Ji P; Li Z; Roy P; Sahajwalla CG J Clin Pharmacol; 2013 Mar; 53(3):314-25. PubMed ID: 23426855 [TBL] [Abstract][Full Text] [Related]
26. Subcutaneous administration of monoclonal antibodies: a small space to inject, a big challenge to conquer. Shameem M Ther Deliv; 2016; 7(1):5-6. PubMed ID: 26652618 [No Abstract] [Full Text] [Related]
27. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001 [TBL] [Abstract][Full Text] [Related]
28. Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability. Miller MA; Khan TA; Kaczorowski KJ; Wilson BK; Dinin AK; Borwankar AU; Rodrigues MA; Truskett TM; Johnston KP; Maynard JA J Pharm Sci; 2012 Oct; 101(10):3763-78. PubMed ID: 22777686 [TBL] [Abstract][Full Text] [Related]
29. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. Haraya K; Tachibana T; Nezu J Xenobiotica; 2017 Mar; 47(3):194-201. PubMed ID: 27151820 [TBL] [Abstract][Full Text] [Related]
30. Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies. Lou H; Hageman MJ Pharm Res; 2021 Mar; 38(3):451-460. PubMed ID: 33710513 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties. Hu S; Datta-Mannan A; D'Argenio DZ AAPS J; 2022 Dec; 25(1):5. PubMed ID: 36456779 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of In Vitro Tools to Predict the In Vivo Absorption of Biopharmaceuticals Following Subcutaneous Administration. Bender C; Eichling S; Franzen L; Herzog V; Ickenstein LM; Jere D; Nonis L; Schwach G; Stoll P; Venczel M; Zenk S J Pharm Sci; 2022 Sep; 111(9):2514-2524. PubMed ID: 35429492 [TBL] [Abstract][Full Text] [Related]
33. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. Yehuda S; Padler-Karavani V Front Immunol; 2020; 11():21. PubMed ID: 32038661 [TBL] [Abstract][Full Text] [Related]
34. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. Xu Z; Wang Q; Zhuang Y; Frederick B; Yan H; Bouman-Thio E; Marini JC; Keen M; Snead D; Davis HM; Zhou H J Clin Pharmacol; 2010 Mar; 50(3):276-84. PubMed ID: 19940229 [TBL] [Abstract][Full Text] [Related]
35. Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. Mahmood I; Tegenge MA J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S108-S116. PubMed ID: 34185903 [TBL] [Abstract][Full Text] [Related]
37. Management of moderate to severe plaque psoriasis with biologic therapy. Pariser DM Manag Care; 2003 Apr; 12(4):36-44. PubMed ID: 12747028 [No Abstract] [Full Text] [Related]
38. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766 [TBL] [Abstract][Full Text] [Related]
39. Jet injection of a monoclonal antibody: A preliminary study. Hogan NC; Cloutier AM; Hunter IW Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():7336-40. PubMed ID: 26737986 [TBL] [Abstract][Full Text] [Related]